capreomycin structure
|
Common Name | capreomycin | ||
---|---|---|---|---|
CAS Number | 11003-38-6 | Molecular Weight | 766.784 | |
Density | N/A | Boiling Point | 1376.7ºC at 760 mmHg | |
Molecular Formula | C25H46N14O12S | Melting Point | N/A | |
MSDS | N/A | Flash Point | 786.4ºC |
Use of capreomycinCapreomycin is a macrocyclic peptide antibiotic. Capreomycin can be used for anti-multidrug-resistant-tuberculosis research. Capreomycin can inhibit phenylalanine synthesis in in mycobacterial ribosomes translation[1][2] |
Name | 3,6-Diamino-N-{[(8Z)-15-amino-11-(2-amino-3,4,5,6-tetrahydro-4-pyrimidinyl)-8-[(carbamoylamino)methylene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentaazacyclohexadecan-5-yl]methyl}hexanamide sulfate (1:1) |
---|---|
Synonym | More Synonyms |
Description | Capreomycin is a macrocyclic peptide antibiotic. Capreomycin can be used for anti-multidrug-resistant-tuberculosis research. Capreomycin can inhibit phenylalanine synthesis in in mycobacterial ribosomes translation[1][2] |
---|---|
Related Catalog | |
Target |
Mycobacterial[1] |
In Vivo | Capreomycin (1.4, 7.2, and 14.5 mg/kg for inhale; 20 mg/kg for i.m.; 4 weeks) decreases the wet lung weight and lowers bacterial burden in the lungs of infected guinea pigs[2]. Animal Model: Male guinea pigs [836 ± 162.3 g; infected via the respiratory route with nebulized suspensions 2 × 105 CFU/mL of Mycobacterium tuberculosis (strain H37Rv)][2] Dosage: 1.4, 7.2, and 14.5 mg/kg for inhale; 20 mg/kg for i.m. Administration: Inhaling or i.m.; 4 weeks Result: Significantly decreased the wet lung weight at 14.5 mg/kg, and smaller than receiving 1.4 mg/kg group and controls. Significantly lowered bacterial burden in the lungs (3.52 ± 0.20 CFU/mL; P < 0.05) at 14.5 mg/kg than controls (4.58 ± 0.20 CFU/mL) and at 1.4 and 7.2 mg/kg (4.02 ± 0.32 and 4.01 ± 0.29 CFU/mL, respectively). |
References |
Boiling Point | 1376.7ºC at 760 mmHg |
---|---|
Molecular Formula | C25H46N14O12S |
Molecular Weight | 766.784 |
Flash Point | 786.4ºC |
Exact Mass | 766.314026 |
PSA | 480.83000 |
Vapour Pressure | 0mmHg at 25°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
3,6-diamino-N-(((8E)-15-amino-3,6,9,12,16-pentahydroxy-8-(((hydroxy(imino)methyl)amino)methylene)-2-(hydroxymethyl)-11-(2-iminohexahydropyrimidin-4-yl)-1,4,7,10,13-pentaazacyclohexadeca-3,6,9,12,16-pentaen-5-yl)methyl)hexanimidic acid compound with sulfuric acid (1:1) |
3,6-Diamino-N-{[(8Z)-15-amino-11-(2-amino-3,4,5,6-tetrahydro-4-pyrimidinyl)-8-[(carbamoylamino)methylene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentaazacyclohexadecan-5-yl]methyl}hexanamide sulfate (1:1) |
Hexanamide, 3,6-diamino-N-[[(8Z)-15-amino-8-[[(aminocarbonyl)amino]methylene]-11-(2-amino-3,4,5,6-tetrahydro-4-pyrimidinyl)-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentaazacyclohexadec-5-yl]methyl]-, sulfate (1:1) (salt) |